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Chronic myelogenous leukemia (CML) is a clonal disorder believed to originate
in a primitive hematopoietic stem cell. During the initial course, leukemic cells in
CML retain the capacity to differentiate and to mature. This period, referred to
as stable phase (SP), antedates an acute blastic phase (blast crisis; BC), which is
associated with loss ofability ofleukemic cells to undergo differentiation and matu-
ration. The primary defect that results in an increased mass of myeloid cells is not
completely understood. It has been suggested, however, that not an unregulated
proliferation but rather a discordant maturational process may contribute to the
abundant production of mostly mature myeloid elements in SP CML (1). Since the
proliferative potential of myeloid progenitor cells (MPC) from SP CML patients
has shown to be impaired compared with the proliferative capacity of MPC derived
from normal human bone marrow (2), it has been suggested that in CML the majority
ofthe malignant cells could have been expanded in latermaturational compartments
(i.e., promyelocytes/myelocytes) (1). Recently, it has been shown that production of
growth factors occurs in some malignant populations ofboth myeloid(3, 4) andlym-
phoid (5) neoplasms, leading to autonomous growth. This study was therefore de-
signed to investigate whether similar mechanisms might also contribute to the ex-
pansion of the myeloid compartment in CML.
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Materials and Methods
BriefDefinitive Report
RNA andDNA Analysis.
￿
Total cytoplasmic RNA from freshly isolated low density bone
marrow-derived leukemic cells of 54 patients with CML was hybridized to a 12P-labeled gran-
ulocyte CSF (G-CSF) cDNA probe (6). RNA extraction was performed according to a previ-
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ously described protocol (7). In addition to probing for G-CSF, in selected cases RNA was
also probed with cDNA specific for IL-3 and granulocyte/macrophage CSF (GM-CSF)
(provided by D. Krumwieh, Behringwerke, Marburg, FRG), M-CSF (provided by P. Ralph,
Cetus Corp., Emeryville, CA), and IL-6 (provided by T. Hirano, Osaka University, Osaka,
Japan). In addition, RNA obtained from subpopulations of SP CML blood cells was ana-
lyzed. In all cases RNA was also hybridized to an a-actin cDNA (kindly provided by R. J.
Schwartz, Houston, TX) to control for RNA loading. DNA blotting was performed after
restriction endonuclease cutting of DNA derived from bone marrow samples of all 54 pa-
tients with the enzymes Hind III, Bgl II, Barn HI, Eco RI as described (8). As germline
control DNA derived from normal bone marrow-derived low density cells was used. All blots
were rehybridized to a 2-kb Bgl II/Hind 111 5' bcr probe (kindly provided by C. Bartram,
Ulm, FRG) to exclude incomplete digestion or overdigestion and showed rearranged bcr se-
quences.
Purification ofSubsets of Cellsfrom CML Blood.
￿
The method of purification of various sub-
populations of cells from CML blood has been previously reported (9) involving the use of
a panel of mAbs (10) and an immune rosette technique to positively or negatively select for
CML blood cell subsets. mAbs used are directed against the following antigens: CD2, CD3,
(T cells), CD10, CD19, CD20 (B cells), CD16 (NK cells and mature neutrophils), CDllb
(pan myeloid), CD14 (monocytes), CD33 (early myeloid), CD34 (hematopoietic progenitor
cells), HLA-DR, glycophorin A (nucleated red cells). To prepare blastcell-enriched fractions
(Be-F), PMNC were depleted from CD2, 3, 10, llb, 16, 19, 29, glycophorin A-positive cells.
Promyelocyte/myelocyte-enriched fractions (P/M-eF) were obtained following depletion of
HLA-DR, CD2, 3, 10, 16, 19, 20, 34, glycophorin A, CD16-positive cells and subsequent
selection of CD33 positive cells. To prepare granulocyte-enriched fractions (GRAN) dex-
tran-sedimented PBC were positively selected for CD16' cells.
Detection of Biologically Active G-CSF in Culture Supernatants of Subsets of Cells from CML
Blood. Secretion of the G-CSF protein by PBC-derived leukemic cell subpopulations was
assayed in a standard two-layer agar (bacto-agar, Difco Laboratories, Detroit, MI) normal
bone marrow day 7 CFU-G assay (10) in the presence or absence of 750 neutralizing U/ml
of a mAb to G-CSF (neutralizing concentrations of all anticytokine mAbs used in this study
were defined by the manufacturers). To this end, individual cell fractions of three stable phase
CML patients were cultured at 106 cells/ml in Iscove's modified Dulbeccds medium (IMDM)
supplemented with 10% FCS. After 48 h of culture, cell-free culture supernatants were har-
vested and incorporated (15% vol/vol) into a CFU-G assay (9, 10).
Results and Discussion
Leukemic cells were obtained before chemotherapy in 54 patients with CML, 27
diagnosed as having stable phase disease and 27 with myeloid blastic phase. In leu-
kemic cells of all patients the Philadelphia chromosome (Phi ) abnormality (11) and
rearranged c-abl/bcr sequences (12) were detected (not shown). In five of nine pa-
tients with acute blastic phase, an additional chromosomeabnormality, an isochromo-
some 17q [i(17q)] disclosed clonal evolution. RNA was extracted from leukemic popu-
lations ofbone marrow specimens ofall 54 patients and hybridized to G-CSF-specific
cDNA (Fig. 1). Accumulation ofG-CSF transcripts was detected in 10 of 27 SP samples
(Fig. 1 A, bottom paneo and in 4 of 27 acute blastic phase samples, two of whom had
i(17q). To define the cell population responsible for the G-CSF synthesis by SP CML
cells, a first set ofexperiments was performed analyzing RNA from peripheral blood
cells for G-CSF transcripts in comparing with transcripts of G-CSF previously ob-
tained from bone marrow samples. In these experiments (not shown), G-CSF mRNA
was also detectablein five peripheral blood-derived leukemic samples offive different
samples investigated, thus excluding the possibility of G-CSF synthesis by mesen-
chymal bone marrow cells. In additional experiments (Fig. 2), density separationKLEIN ET AL .
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FIGURE 1 . Accumulation of
G-CSFmRNA in bone marrow
cells from patients with stable
phase (SP) (f1, bottompanel) and
acute blastic phase (BC)CML
(B, toppanes. The control lane
represents RNA derived from
IFN-y (50 ng/ml) activated
(aMO) and unstimulated pe-
ripheral blood monocytes (MO)
of healthy donors probed with
the G-CSF cDNA . (B) North-
ern blots of all SP and BC-
derivedRNA samples express-
ing G-CSF transcripts probed
with cDNAs specific for M-CSF,
IL-6, GM-CSF, and IL-3 . Con-
trol lanes (CO) representRNA
derived from stimulated mono-
cytes (for G-CSF and M-CSF)
and from PMNC stimulated
with phytohemagglutinin (2 ug/
ml) and phorbol myristic acid
(10 -y M) (for GM-CSF and
IL-3) .
and a panel of mAbs followed by immune rosetting were used to obtain cell sub-
populationsthat were enriched for promyelocytes/myelocytes (>,97% pure), forma-
ture granulocytes (>99% pure), and forblast cells (>94% pure)by positive and nega-
tive selection procedures . G-CSFcDNA that was hybridized toRNA derived from
enriched populations failed to detectably hybridize with blast cell-derived RNA.
Specific signals, however, appeared when RNA from P/M-eF (giving the strongest
signal) and GRAN (giving the weakest signal) were investigated (Fig . 2 B) . Simi-
larly, supernatants of cultures ofblood mononuclear cells and theirpromyelocyte/my-
elocyte and granulocyte subpopulations, but not blast cell fractions, displayed bio-
logic activity for G-CSF when tested on purified normal bone marrow-derived
granulocyte colony-forming (CFU-G) cells (Fig. 2A) . To investigatewhethermaturing
leukemic cells producing G-CSF also responded to this factor by stimulating their
own growth in an autocrine fashion, SPCML cells enriched for promyelocytes/my-
elocytes were cultured in semisolid agar in the presence or absence of neutralizing1788
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andnonneutralizing mAbs to recombinant human (rh) G-CSF and were investigated
for their ability to generate clones . Fig . 3 shows that P/M-eF ofCML populations
generated up to 60 clones/103 cells over a period of 7 d, which could be inhibited
by treating the cultures with neutralizing mAb to G-CSF, thus demonstrating that
CML-derived promyelocytes/myelocytes use autocrinously secreted G-CSF to spur
their own terminal divisions . It should be noted that anti-G-CSF antibody had no
inhibitory effect on clonal growth ofCML cultures established with cells not ex-
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FIGURE 2 .
￿
Expression of the
G-CSF mRNA in subsets of
PBC-derived leukemic cells of
a patient (patient 14, see Fig . 1
A, bottompanel) with SP CML.
Theopen bar represents a con-
trol in which CFU-G growth
was stimulated with medium
only.The other bars correspond
to the slots shown inB. a-Actin
cDNA controls for RNA load-
ing . Identical experiments were
performed with subsets ofPBC-
derived leukemic cells of two
otherpatients (patients 5and 6,
see Fig . 1 A, bottom panel) and
showed comparable results .
FIGURE 3 .
￿
In vitro generation
ofclones by promyelocyte/my
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elocyte enriched fractions of
PMNC (SPCML patients) in
9
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semisolid agar (patient 14, Fig .
1 A, bottom pano . The figure
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shows size distribution ofclones
generated overa culture period
of 7 d . In A cells were cultured
in medium only. In B the cul-
tures were treated with a neu-
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and IL-6 did not abrogate the
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generation ofclones (not shown).
In all experiments cells were
cultured at 1,000 cells/ml in a
e
￿
mixture of 1 vol of double-
strength IMDM, 1 vol of FCS,
4
￿
and2 vol of0.6% bacto-agar in
24-well plates (Linbro). Thecul-
tures were incubated at 37'C in
2
￿
a humidified atmosphere of 10%
C02 in air . Replicate cultures
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were scored at intervals between
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days 1and 7 ofincubation using
Day
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a dissection microscope as de-
scribed (13).KLEIN ET AL .
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F[GURE 4. Southern blot analysis of
DNA digested with Hind III (A) derived
from lowdensity bone marrow cells oftwo
patients (patients 6 and 13) with blastic
phaseCMLprobingwith aG-CSF cDNA.
(B) DNA blots ofDNA from low density
bone marrow cells of patient 13 digested
with Bgl II, Barn HI, andEcoRI, probed
with aG-CSFcDNA (P) . As germline con-
trol (CO)DNAderived from normal bone
marrow low density cells was used . Incom-
plete digestion or overdigestion was ex-
cluded by demonstrating rearranged bcr se-
quences following rehybridization with a
specific probe (not shown) .
pressing the G-CSF gene . Since both SP andBCCML that expressed G-CSF also
accumulated transcripts ofM-CSF (9 of 14), IL-6 (12 of 14), but not ofGM-CSF
and IL-3 (Fig . 1 B), identical experiments were performed using neutralizing con-
centrations ofmAbs to rh M-CSF(kindly providedbyP Ralph) andto rhIL-6 (kindly
provided byT . Hirano) . Anti-M-CSF and anti IL-6 mAbs were, however, unable
to prevent generation of clones by P/M-eF ofSP CML cells . Of the four G-CSF
mRNA expressing BC CML samples investigated, only one grew autonomously in
agar (patient 13, see Figs . 1 t1, fop panel; and 4, A, B) . However, none of the an-
ticytokine mAbs used (anti-G-CSF, -M-CSF, -IL-6) were capable of inhibiting au-
tonomous blast growth, even when used in high concentrations (2,000 neutralizing
U/ml) and in combinations (data not shown) .
Normal blood or nonmesenchymal bone marrow cells da not secrete hematopoi-
etic growth factors unless activated (3, 4) ; thus, constitutive expression of G-CSF
byCML cells must be ranked as highly abnormal . Recently, rearrangement of the
gene for GM-CSF has been shown to result in expression of theGM-CSF gene in
some cases ofacutemyelogenousleukemia (14) . Therefore, we searched forgenomic
alterations of the G-CSF, M-CSF, and IL-6 gene in all our patients . Restriction en-
donuclease analysis and Southern blotting revealed germline configurations of the
G-CSF gene forDNA samples of 52 patients and of the M-CSF and IL-6 gene in
all 54 patients (data not shown) . Nongermline G-CSF gene-related fragments of
variable sizes were, however, detected in two of nine cases ofBC CML with i(17q),
the chromosome to which the G-CSF gene had been assigned (15), thus suggesting
that the i(17q) may occasionally bear a breakpoint within the G-CSFgene . Further
work to analyze this chromosome region is being actively pursued in ourlaboratory.
Summary
In this paper we demonstrate that maturing neoplastic cells from patients with
chronic myelogenous leukemia (CML) constitutively produce G-CSF and are also1790
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receptive for this molecule. G-CSF functions as an autocrine growth factor in stable
phase CML, and thus is responsible for divisions of maturing leukemic cellsleading
to an expansion of the compartment of mature cells. This observation is well in line
with in vivo features of CML in stable phase, i.e., the hyperplasia of the mature
granulocyte compartment. In acute blastic phase ofCML expression of the G-CSF
gene seems to be less common and not related to autonomous blast growth.
Received for publication 27 February 1989 and in revised form 13 February 1990.
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